Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126

Current experimental and clinical knowledge supports the optimisation of endothelial cell targeting using a strategy combining anti-EGFR drugs with antivascular agents. The purpose of the present study was to examine the effects of the association of ZD6126, an antivascular microtubule-destabilising...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozec, A, Lassalle, S, Gugenheim, J, Fischel, J-L, Formento, P, Hofman, P, Milano, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360508/
https://www.ncbi.nlm.nih.gov/pubmed/16940984
http://dx.doi.org/10.1038/sj.bjc.6603308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360508/
https://www.ncbi.nlm.nih.gov/pubmed/16940984
http://dx.doi.org/10.1038/sj.bjc.6603308

Ejemplares similares